Combined pharmaceutical composition

Details Combined pharmaceutical composition Combined pharmaceutical composition

A - Human Necessities

61

K

A61K 31/192 (2006.01) A61K 31/194 (2006.01) A61K 31/216 (2006.01) A61K 31/22 (2006.01) A61K 31/366 (2006.01) A61K 31/40 (2006.01) A61K 31/405 (2006.01) A61K 31/4418 (2006.01) A61K 31/445 (2006.01) A61K 31/47 (2006.01) A61K 31/7008 (2006.01) A61K 31/702 (2006.01) A61K 45/00 (2006.01) A61P 1/16 (2006.01) A61P 3/00 (2006.01) A61P 3/04 (2006.01) A61P 3/06 (2006.01) A61P 3/10 (2006.01) A61P 9/00 (2006.01) A61P 9/12 (2006.01) A61P 13/12 (2006.01) A61P 19/08 (2006.01) A61P 19/10 (2006.01) A61P 25/00 (2006.01) A61P

Patent

CA 2555316

A drug which contains a combination of the active ingredients comprising at least one remedy for hyperlipemia selected from the group consisting of fibrate compounds (phenofibrate, bezafibrate, salts thereof, etc.) and HMG-CoA reductase inhibitors (statin compounds such as pravastatin, atorvastatin, salts thereof, etc.) with an .alpha.-glucosidase inhibitor (voglibose, acarbose, etc.). The content of the .alpha.-glucosidase inhibitor may be from 0.001 to 50 parts by weight per 100 parts by weight of the remedy for hyperlipemia. Thus, it is possible to provide a drug having excellent effects of preventing and/or treating metabolic syndrome, hyperlipemia, diabetes, diabetic complications, etc. with little side effect.

Médicament contenant une combinaison des ingrédients actifs comprenant au moins un remède contre l'hyperlipémie, choisi parmi le groupe constitué des composés fibrates (phénofibrate, bézafibrate, leurs sels, etc.) et d'inhibiteurs HMG-CoA réductase (composés de statine tels que la pravastatine, l'atorvastatine, leurs sels, etc.) avec un inhibiteur de alpha-glucosidase (voglibose, acarbose, etc.). La teneur en inhibiteur de alpha-glucosidase peut être de 0,001 à 50 parties en poids pour 100 parties en poids du remède contre l'hyperlipémie. Ainsi, il est possible de fournir un médicament ayant d'excellents effets de prévention et/ou de traitement du syndrome métabolique, de l'hyperlipémie, du diabète, des complications dues au diabète, etc., avec peu d'effets secondaires.

Affiliated with

Also associated with

Rating

Combined pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combined pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined pharmaceutical composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1820630